Abaloparatide
Also known as: Tymlos, Eladynos, BA058
A synthetic PTHrP analog that builds bone, FDA-approved as Tymlos for osteoporosis at high fracture risk. Prescription medication.
Last updated
Mechanism of Action
Abaloparatide is a 34-amino-acid synthetic analog of parathyroid hormone-related protein (PTHrP 1-34) that activates the PTH type 1 receptor (PTH1R) on osteoblasts. It binds preferentially to the receptor's RG conformation, producing shorter cAMP signaling than PTH. Given as a once-daily pulse, this favors bone formation over resorption, raising bone mineral density and lowering fracture risk.
- Half-life
- ~1.7 hours
- Administration Routes
- Subcutaneous
- Research Status
- Clinical
Reported Benefits
- Reduces new vertebral fractures in postmenopausal women with osteoporosis
- Reduces nonvertebral fractures versus placebo in the ACTIVE trial
- Increases bone mineral density in men with osteoporosis at high fracture risk
- Typically followed by an antiresorptive to maintain gains
Potential Side Effects
- Orthostatic hypotension and dizziness, mostly after early doses
- Hypercalcemia and hypercalciuria (kidney stone risk)
- Nausea, headache and palpitations or fast heart rate
- Osteosarcoma in rat studies (the former boxed warning was removed in 2021)
Common Dosing
Labeled dosing is 80 mcg injected subcutaneously into the abdomen once daily, with calcium and vitamin D supplementation if dietary intake is inadequate. The label states that use for more than 2 years during a patient's lifetime is not recommended. Dosing is set and supervised by the prescribing clinician.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Increased baseline osteosarcoma risk (Paget's disease, open epiphyses, prior skeletal radiation): avoid
- Pre-existing hypercalcemia or hyperparathyroidism
- Active or recent kidney stones (use with caution)
No documented stacking partners for Abaloparatide yet.
- View
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial
2016
- View
The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
2022
- View
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
2019